Clinical Trial

Effect of Propofol Versus Remimazolam Intravenous Anesthesia on Respiratory Depression

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 10, 2025 (before its estimated January 2026 completion). Its status may not reflect the trial's current state.
Summary
General anesthesia is the preferred choice for pediatric patients, but the induction of volatile anesthetics via face mask may cause preoperative anxiety and postoperative delirium. Total intravenous anesthesia (TIVA) is more suitable for pediatric patients, as it can effectively alleviate preoperative anxiety, reduce the risk of postoperative delirium and mania, shorten hospital stay, reduce medical burden, and increase parental satisfaction. Propofol, although effective for anesthesia, has drawbacks such as injection pain and respiratory and circulatory suppression. Remimazolam is a novel ultra-short-acting benzodiazepine drug, which has no injection pain, minimal impact on respiration and circulation, and rapid onset and elimination, making it suitable for children. However, research on remimazolam in children is limited. This study aims to compare the effect of propofol and remimazolam intravenous anesthesia combined with regional or caudal block on respiratory depression in preschoolers.
Trial Details
NCT Number NCT06816173
Lead Sponsor Second Affiliated Hospital of Wenzhou Medical University
Conditions Respiratory Depression
Enrollment 96 participants
Start Date 2025-02
Primary Completion 2026-01 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-02-10